Skip to main content
News Icon

News categories: Publication

COVID-19: Immune system gone astray

Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Experts from Charité - Universitätsmedizin Berlin, the University of Bonn, the German Center for Neurodegenerative Diseases (DZNE), the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF), along with colleagues from a nationwide research network, present these findings in the scientific journal "Cell".

Most patients infected with the novel coronavirus SARS-CoV-2 show mild or even no symptoms. However, 10 to 20 percent of patients develop pneumonia during the course of COVID-19 disease, some of them with life-threatening consequences. "There is still not very much known about the causes of these severe courses of the disease. The high inflammation levels measured in those affected actually indicate a strong immune response. Clinical findings, however, rather indicate an ineffective immune response. This is a contradiction," says Joachim Schultze, professor at the University of Bonn and member of the Cluster of Excellence ImmunoSensation.

"We therefore assumed that immune cells are produced in large quantities, but that their function is defective. Therefore, we analyzed the blood of patients with varying degrees of COVID-19 severity," explains Leif Erik Sander, Professor of Infection Immunology and Senior Physician at Charité's Medical Department, Division of Infectious Deseases and Respiratory Medicine. The investigations involved single-cell OMICs technologies, a collective term for modern laboratory methods used to determine, for example, the gene activity and the amount of proteins on the level of individual cells - thus with very high resolution.

Using this data, the scientists characterized the properties of immune cells in the blood - so-called white blood cells. The researchers found out that neutrophils and monocytes were activated during a case of mild disease courses and could thereby initiate and effective immune response. In contrast, the situation is different in severe cases of COVID-19, where neutrophils and monocytes are only partially activated and they do not function properly. There are more immature cells that have a rather inhibitory effect on the immune response. The findings indicate that the immune system stands in its own way during severe courses of COVID-19.

"If the case of excessive dysfunctional immune cells, as our study shows, one would however very much wish to suppress or reprogram such cells.", says Anna Aschenbrenner LIMES Institute at the University of Bonn.

Jacob Nattermann, Professor at the Medical Clinic I of the University Hospital Bonn and head of a research group at the DZIF, further explains: "Drugs that act on the immune system might be helpful. But this is a delicate balancing act. After all, it's not a matter of shutting down the immune system completely, but only those cells that slow down themselves, so to speak. In this case these are the immature cells. We can possibly learn from cancer research. There is experience with therapies that target these cells."


Publication

Severe COVID-19 is marked by a dysregulated myeloid cell compartment, Schulte-Schrepping et al., CELL (2020), DOI: 10.1016/j.cell.2020.08.001

Related news

News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview